Related references
Note: Only part of the references are listed.Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
Karim Fizazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Denosumab: Anti-RANKL antibody
Paul D. Miller
Current Osteoporosis Reports (2009)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy
Allan Lipton et al.
CLINICAL CANCER RESEARCH (2008)
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
Georgiana K. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effects of denosumab on bone resorption in patients with solid tumors and bone metastases: Comparison of serum-C telopeptide levels from two randomized, active-controlled, phase II trials
J. R. Gralow et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Loss of treatment benefit due to low compliance with bisphosphonate therapy
F. J. A. Penning-van Beest et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD
E. Michael Lewiecki et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone Metastases
Allan Lipton et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
RANK ligand inhibition with denosumab for the management of osteoporosis
E. Michael Lewiecki
EXPERT OPINION ON BIOLOGICAL THERAPY (2006)
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases
Ethel S. Siris et al.
MAYO CLINIC PROCEEDINGS (2006)
Denosumab in postmenopausal women with low bone mineral density
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
JJ Body et al.
CLINICAL CANCER RESEARCH (2006)
Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease - Potential uses and pitfalls
Serge Cremers et al.
DRUGS (2006)
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength
PJ Kostenuik
CURRENT OPINION IN PHARMACOLOGY (2005)
Mechanisms of disease: Mechanisms of bone metastasis
GD Roodman
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women
PJ Bekker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Metastasis to bone: Causes, consequences and therapeutic opportunities
GR Mundy
NATURE REVIEWS CANCER (2002)
Share Paper
